gatipotuzumab
mAbexperimental
Clinical trial activity
3 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Nov 1, 2009 (NCT01222624)
Timeline
Indications
Mechanism of action
- Mucin-1INHIBITOR
Mucin-1 inhibitor
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL4297560 ↗
Also known as
- pankomab-gex
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT03360734 | Phase 1 | Nov 2, 2017 | Glycotope GmbH |
| NCT01899599 | Phase 2 | Sep 1, 2013 | Glycotope GmbH, University of London |
| NCT01222624 | Phase 1 | Nov 1, 2009 | Glycotope GmbH |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Glycotope GmbH | For profit | 3 | 3 | 2 | 2009 |
| University of London | Academic/Hospital | 1 | 0 | 1 | 2013 |
2 organizations
Page 1 / 1